Ireland
--:--IST
Recruiting Observational

A Comparative Study Between Neutrophil/Lymphocyte Ratio and Lactate/Albumin Ratio as Predictive Inflammatory Markers for Sepsis

NCT07089524 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2024-09-11
Last updated
2025-07-28

Condition(s) studied

Sepsis

Study summary

Aim of this study is to predict the prognostic values of Neutrophil/ Lymphocyte ratio and Lactate/Albumin ratio in the outcome of patients with sepsis and septic shock with lower respiratory tract infection, also to compare between them regarding sensitivity and specificity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Adults with lower respiratory tract infection * Confirmed septic patients (under the third international consensus definitions of sepsis and septic shock), * Admitted to intensive care unit. * Age (18-80) years. * Both genders. Exclusion Criteria: * Age: \< 18 years old, \> 80 years old * Patient refusal. * Pregnancy. * Malignancy. * Pathology that could affect serum albumin concentrations prior to ICU admission as Malnutrition * Nephrotic syndrome * Liver Cirrhosis * Intestinal resection surgeries

Primary outcome measure(s)

  • Detect the mortality due to sepsis with lower respiratory tract infection — From date of randomization until the date of death during the study period ( 12-18 months)
    Detect the mortality due to sepsis and septic shock in patients with lower respiratory tract infection in ICU
  • The prognostic values of Neutrophil/Lymphocyte ratio and Lactate/Albumin ratio in Sepsis — From date of randomization until the date of discharge from the ICU or death during the study period ( 12-18 months )
    predict the prognostic values of Neutrophil/Lymphocyte ratio and Lactate/Albumin ratio in the outcome of septic patients with lower respiratory tract infection in ICU

Trial sites (1)

FacilityCityRegionStatus
Ain Shams university Cairo Abbassia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07089524 on ClinicalTrials.gov ↗ ← All trials in Egypt